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Background: The lower sales price of generic lamivudine has caused healthcare administrators to consider
abolishing fixed-dose antiretroviral combinations (FDCs) that contain lamivudine and emtricitabine. The alternative
is to administer the individual components of the FDCs separately, thus incorporating the new generic
lamivudine medication.
Methods: The Balearic Islands Health Service ordered the discontinuation of the treatment with FDCs in July 2010,
but FDCs were reintroduced in August 2010. At that point, an independent, retrospective cost analysis was
performed by Son Llàtzer Hospital. A total of 75 patients who were treated from July to August 2010 underwent
replacement of their FDC treatment with the individual components. Additionally, 150 patients who continued
using FDCs were randomly selected. For both patient groups, the antiretroviral therapy that was administered and
the costs associated with management of adverse events were recorded. The study period used for the cost
calculations was the average number of days that patients used separate components of FDCs (120 days). An
alternative analysis was performed to consider the costs of the extra follow-up visit (consultation and clinical tests)
that was required for patients who changed their antiretroviral therapy.
Results: Considering antiretroviral therapies and adverse events, the administration of the separate components
increased the total daily cost by 0.72 € per patient compared to treatment with FDCs. When the cost of an extra
follow-up visit was considered, the daily cost increased by 3.61 € per patient.
Conclusions: Our study suggests that the discontinuation of FDC treatment and the replacement with the
administration of separate antiretroviral agents could lead to an increase in healthcare costs due to the higher rate
of adverse events that was observed with the discontinuation of FDCs.
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Human immunodeficiency virus (HIV) is a retrovirus of
the Lentivirus genus. The infection produced by HIV leads
to the development of the acquired immunodeficiency syn-
drome (AIDS). HIV preferentially attacks CD4+ cells, a
type of T lymphocyte, which prevents the immune system
from reacting to opportunistic infections that are produced
by other viruses, bacteria, or fungi. According to the latest
World Health Organisation (WHO) data in December
2011, the number of people infected by HIV is estimated
to be 34 million [1]. In 2010, 1.8 million people died as a
consequence of illnesses related to AIDS, which makes this
pandemic disease the fourth leading cause of mortality
worldwide [1].
Because of the complexity associated with the selection
of a specific treatment, the severity of the related side
effects and the necessity of preventing the appearance of
resistant viral strains, the current treatment of HIV-1 is
based on a combination of antiretroviral agents. This
therapy, known as “highly active antiretroviral therapy”
(HAART), has evolved over the years from a regimen of
more than 20 pills per day to a single daily pill that com-
bines fixed doses of several antiretroviral agents [2].
Antiretroviral therapy (ART) should be administered
indefinitely to patients infected with HIV-1. The therapy,
which has possible short- and long-term side effects,
requires constant therapeutic compliance to complex
drug regimens. Fixed-dose antiretroviral combinations
(FDCs) have led to the simplification of antiretroviral
therapy, which has improved patient quality of life and
treatment compliance [3].
Due to the current economic crisis and budget restric-
tions, the arrival of generic lamivudine with a more com-
petitive sales price has led some healthcare administrators
to consider breaking up FDCs that contain lamivudine
(3TC) and emtricitabine (FTC), and administrating theAtriplaTM






(zidovudine / lamivudine / abacavir)
TruvadaTM
(TDF / emtricitabine)
Figure 1 Schematic FDCs separation to individual antiretroviral agentseparate components that includes the new generic lami-
vudine. FDCs containing emtricitabine, such as AtriplaTM
(efavirenz, emtricitabine, and tenofovir) and TruvadaTM
(emtricitabine and tenofovir), have also been subject to
interruptions in favour of the administration of the separ-
ate components. In these cases, the emtricitabine compo-
nent was substituted with generic lamivudine.
To estimate the effect of this decision at Son Llàtzer
Hospital, a retrospective study was performed to analyse
information about the administration of ART and the
healthcare resources that are used to manage adverse
events (AEs). In the present study, an analysis of the ART
and AEs associated costs was performed for patients trea-
ted with FDCs and for patients treated with combinations
of separately administered antiretrovirals.
Methods
An independent, retrospective study was conducted at Son
Llàtzer Hospital between June 2010 and July 2011. Infor-
mation regarding ART and the management of AEs was
collected from patients infected with HIV-1. A total of 75
patients experienced the substitution of their FDC treat-
ment with individual antiretroviral agents (exposed group).
The schematic in Figure 1 represents how the FDCs were
breaking down. The medications CombivirTM (lamivudine
and zidovudine), KivexaTM (abacavir and lamivudine), and
TrizivirTM (abacavir, lamivudine, and zidovudine) were
replaced with the separate administration of their individ-
ual antiretroviral agents; generic lamivudine for KivexaTM
and generic zidovudine and lamivudine for CombivirTM
and TrizivirTM. In contrast, and because generics are still
unavailable for the components of AtriplaTM (efavirenz,
emtricitabine, and tenofovir) and TruvadaTM (emtricitabine
and tenofovir) emtricitabine was replaced with generic
lamivudine, which is perceived to be equivalent to
emtricitabine.VireadTM (TDF) + generic lamivudine +
+ SustivaTM (efavirenz)
generic zidovudine + generic lamivudine
generic lamivudine + ZiagenTM (abacavir)
generic zidovudine + generic lamivudine +
+ ZiagenTM (abacavir)
VireadTM (TDF) +  generic lamivudine
s.
Homar et al. Health Economics Review 2012, 2:16 Page 3 of 9
http://www.healtheconomicsreview.com/content/2/1/16Using a hospital database of 434 patients with controlled
HIV, 150 patients observed between March and November
2010, and who continued receiving FDCs, were randomly
selected (non-exposed group); these patients continued re-
ceiving FDCs because their expected appointment dates
preceded the FDCs disruption. The following baseline
characteristics were recorded for both group of patients:
gender, age, weight, date of HIV diagnosis, mechanism of
transmission, history of AIDS, HCV infection status, psy-
chiatric history, current use of methadone or psychophar-
maceuticals, date of efavirenz initiation, date of FDC
initiation and type, non-nucleoside analogue reverse tran-
scriptase inhibitor use, protease inhibitor use, and integrase
inhibitor use (Table 1).
For the exposed group, the baseline visit was defined as
the date on which the FDC change was performedTable 1 Baseline patient characteristics
Exposed patients (n = 75)
Gender (female) 18 (24%)










Psychiatric history 17 (23%)
Methadone consumption 5 (6%)










Exposure time to FDCs (months) 27 (range: 1–121)
Exposure time to efavirenz (months) 50 (range: 129–1)
Viral load > 50 copies/mL at visit −1 12 of 74 (16.2%)
Viral load > 50 copies/mL at baseline visit 10 of 74 (13.5%)
CD4 at first visit (cells/μL) 573 (range: 41–1527)
IVDU: intravenous drug user; AIDS: acquired immunodeficiency syndrome; HCV: hep
non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; CD4: CD4+ lym
*No statistically significant differences.(between July and the beginning of August 2010). Data
were also collected from the visit prior to the baseline visit
(visit −1) and from two serial visits after the baseline visit
(visits +1 and +2). For the non-exposed patients, the base-
line visit was the closest visit to July 2010. At each visit, the
CD4+ T lymphocyte counts, HIV-1 viral load, serum glu-
tamic oxalacetic transaminase (SGOT), serum glutamic
pyruvate transaminase (SGPT), cholesterol, LDL-choles-
terol, HDL-cholesterol, triglycerides, and the presence of
AEs were recorded for both group of patients. During the
process of identifying AEs, the potential relationship with
ART was indicated (unrelated or likely related). This deci-
sion was based on the investigator’s criteria and on the
attending physician’s annotations in the patient’s chart (the
temporal relationship and the disappearance or improve-
























24 (range: 3–98) *
61 (range: 126–3) *
8 of 149 (5.4%) (OR: 3.4; 95%CI: 1.3-8.8; p = 0.02)
10 of 146 (6.8%) *
542 (range: 92–1481) *
atitis C virus; FDCs: fixed-dose antiretroviral combinations; NNRTI:
phocytes; OR: odds ratio; 95%CI: confidence intervals at the 95% level.
Table 2 Unit costs of antiretroviral agents
Antiretroviral agent Cost (€)
FDCs
AtriplaTM (TDF / emtricitabine / efavirenz:
245 / 200 / 600 mg), 30 tablets
701.08
CombivirTM (zidovudine / lamivudine:
300 / 150 mg), 60 tablets
290.41
KaletraTM (lopinavir / ritonavir:
200 / 50 mg), 120 tablets
400.02
KivexaTM (lamivudine / abacavir:
300 / 600 mg), 30 tablets
355.54
TrizivirTM (zidovudine / lamivudine / abacavir:
300 / 150 / 300 mg), 60 tablets
490.32
TruvadaTM (TDF / emtricitabine:
200 / 245 mg), 30 tablets
432.73
Individual antiretroviral components of FDCs
Generic lamivudine (300 mg), 30 tablets 62.76
SustivaTM (efavirenz: 600 mg), 30 tablets 265.03
VireadTM (TDF: 250 mg), 30 tablets 288.70
ZiagenTM (abacavir: 300 mg), 60 tablets 225.69
Generic zidovudine (300 mg), 300 tablets 403.15
Other antiretroviral agents employed in addition to FDCs
IntelenceTM (etravirine: 100 mg), 120 tablets 450.00
IsentressTM (raltegravir: 400 mg), 60 tablets 690.00
NorvirTM (ritonavir: 100 mg), 30 tablets 22.46
PrezistaTM (darunavir: 400 mg), 60 tablets 427.21
ReyatazTM (atazanavir: 200 mg), 60 tablets 436.59
ReyatazTM (atazanavir: 300 mg), 30 tablets 436.59
TelzirTM (fosamprenavir: 700 mg), 60 tablets 316.89
ViramuneTM (nevirapine: 200 mg), 60 tablets 199.69
Ex-factory price (€, 2011).
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World Health Organization criteria. The possible reintro-
duction of the FDCs on visits +1 and +2, changes to other
treatments, and failures to follow-up were also recorded.
The average time that the exposed patients were treated
with individual antiretroviral agents (120 days) was used as
a temporal horizon for the cost analysis. Given that this
analysis was performed from a hospital perspective, only
healthcare costs that were directly associated with the
pharmaceutical cost and the cost of managing the AEs
were included. For the cost analysis, only AEs that were
related to ART were considered. The consumption of anti-
retroviral agents was calculated using the posology from
the corresponding Summary of Product Characteristics,
and considering the ex-factory price that results from con-
verting the catalogue price of the Spanish General Council
of Official Colleges of Pharmacists [4] with the established
commercial margins [5] (Table 2). The cost of AEs asso-
ciated with ART was calculated based on the resourceutilisation during AE management. The unit costs of the
healthcare resources were obtained from a Spanish data-
base of healthcare costs [6] (Table 3).
Alternative scenario
In the exposed group, as a consequence of the change in
ART experienced with the replacement of their FDCs, the
Son Llàtzer Hospital scheduled one follow-up visit for
these patients. The costs related to this follow-up visit were
included in an alternative scenario and entail the cost asso-
ciated with the consumption of the following healthcare
resources: a medical appointment, biochemistry, haemo-
gram, coagulation profile, urinalysis, analysis of lymphocyte
populations, and determination of the viral load. The costs
considered in this analysis are expressed in Euros (€) from
2011, and are detailed in Table 3. The study protocol was
approved by the Research Commission of the Son Llàtzer
Hospital. Written informed consent was obtained from the
patients prior to data collection.
Results
The mean age of the patients in the exposed group (n=75)
was 44 years, and in the non-exposed group (n= 150),
46 years. The percentage of women was similar in both
groups of patients, with 24% in the exposed group and
25% in the non-exposed group. There were no statistically
significant differences in the baseline patient characteristics
of the exposed and non-exposed group, including patient
weight, mechanism of HIV transmission, concomitant
pathology, and type of FDC used at the beginning of the
study (Table 1). At visit −1, 12 of 74 (16.2%) exposed
patients and 8 of 149 (5.4%) non-exposed patients had
HIV-1 viral load greater than 50 copies/mL (OR 3.4; 95%
CI: 1.3-8.8; p = 0.02). At the baseline visit, the HIV-1 viral
load was greater than 50 copies/mL in 10 of 74 (13.5%)
exposed patients and in 10 of 146 (6.8%) non-exposed
patients. At visit +1, 5 of 67 exposed patients (7.4%) pre-
sented viral load values greater than 50 copies/mL, whereas
13 of 146 non-exposed patients (8.9%) presented viral load
values greater than 50 copies/mL; at visit +2, viral load
values greater than 50 copies/mL were observed in 9 of 72
exposed patients (12.5%) compared with 9 of 134 non-
exposed patients (6.7%). Except the HIV-1 viral load at visit
−1, none of the other differences were statistically signifi-
cant, and neither was the differences found in the CD4+
cell counts.
In total, 21 AEs (28.0%) were observed in the exposed
group, and 7 AEs (4.7%) were observed in the non-
exposed group. Of the AEs that were likely related to
ART, there were 14 (18.7%) in the exposed group at visit
+1, immediately after discontinuation with the FDC,
compared with 2 (1.3%) in the non-exposed group (OR
16.8; 95%CI: 3.7-76.9; p < 0.001). It should be noted that
the 14 AEs observed in the exposed group were found
Table 3 Unit costs of healthcare resources (€, 2011)
Healthcare resource Unit cost (€)
Consultations
Mental health day centre 49.36

























Erythrocyte sedimentation rate 1.12
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with an emtricitabine containing FDCs, AtriplaTM or
TruvadaTM, (n = 60).No AEs were found in the exposed
patients that were previously treated with a lamivudine
containing FDCs, KivexaTM, CombivirTM or TrizivirTM,
(n = 15).
The differences on AEs likely related with ART at visit
+1 between both groups of patients were extensively
studied. When the AEs were analysed excluding those
patients with HIV-1 viral load greater than 50 copies/mL
at visit −1, statistically significant differences were also
found. In the exposed patients with viral load lower than
50 copies/mL at visit −1 (n = 62), 11 (17.7%) AEs likely
related to ART were found, while only 2 (1.4%) AEs
were observed in the non-exposed group of patients
(n = 141) (OR 14.9; 95%CI: 3.2-70.0; p < 0.001). In
addition, another analysis excluding patients with HIV-1
viral load > 50 copies/mL at baseline visit was carriedout. There were found 13 (20.3%) AEs likely related with
ART at visit +1 in 64 exposed patients compared with 2
(1.5%) AEs found in 136 non-exposed patients (OR 17.0;
95%CI: 3.7-78.3; p < 0.001).
Another analysis was performed excluding those
patients who recently started treatment with FDCs (less
than 6 month of treatment with FDCs at the beginning
of the study). In the exposed group of patients (n = 63),
11 (17%) AEs likely related with ART were observed at
visit +1 compared with 1 (0.7%) AEs in the non-exposed
group (n = 132) (OR 27.1; 95%CI: 3.4-215.8; p < 0.001).
Statistically significant differences were also observed
when the patients who recently started treatment with
efavirenz (less than 6 months) were excluded. In the
exposed group (n = 50), 12 (24.0%) AEs were found com-
pared with 2 (2.4%) AEs in the non-exposed group
(n = 84) (OR 13.5; 95%CI: 2.9-63.5; p < 0.001). The results
of these analyses are summarized in Table 4.
In the group of non-exposed patients, the two
observed AEs that were likely related to ART, were
neuropsychiatric effects and were also likely related to
efavirenz toxicity. One of these patients presented with
dizziness after making an error in taking AtriplaTM,
while the other patient presented with insomnia, anxiety,
and abnormal dreams (Table 5).
Of the 14 exposed patients who presented AEs that
were likely related to ART, 9 patients who had under-
gone prior treatment with AtriplaTM presented with
neuropsychiatric symptoms that were compatible with
efavirenz toxicity, despite undergoing stable treatment
with this agent; the mean time of exposure to efavirenz
was 77 months in the patients with neuropsychiatric
AEs and 44 months in the patients without neuropsychi-
atric AEs (p = 0.01). There were two other cases of
neuropsychiatric AEs in the exposed group, but they
were considered to be unrelated to ART due to the ab-
sence of a suggestive temporal relationship. Additionally,
there were two cases of hepatic toxicity, two cases of
diarrhoea, and one case of vomiting (Table 5).
In the exposed group, with respect to the severity of
the AEs that were likely related to ART, there were two
grade-4 AEs, including one case of toxic hepatitis and
one neuropsychiatric event that included virologic failure
and HIV encephalopathy. Additionally, there were two
grade-3 AEs, including one hepatotoxicity AE and one
neuropsychiatric AE. In these severe grade-3 and grade-
4 AEs, the neuropsychiatric events were found in
patients previously treated with AtriplaTM, while the
cases of hepatotoxicity were found in one patient who
had been previously treated with TruvadaTM and fosam-
prenavir, and in other patient who had undergone previ-
ous treatment with AtriplaTM.
In Figure 2, the flow of exposed and non-exposed
patients during visits +1 and +2 is described.
Table 4 Adverse Events that are likely related to antiretroviral therapy at visit +1
Non-exposed (NE) group Exposed (E) group
Total number of AEs found
NE group: n = 150; E group: n = 75
2 (1.3%) 14 (18.7%) OR 16.8; 95% CI: 3.7-76.9; p < 0.001
Number of AEs excluding patients with
viral load > 50 copies/mL at visit −1
NE group: n = 141; E group: n = 62
2 (1.4%) 11 (17.7%) OR 14.9; 95% CI: 3.2-70.0; p < 0.001
Number of AEs excluding patients with
viral load > 50 copies/mL at baseline visit
NE group: n = 136; E group: n = 64
2 (1.5%) 13 (20.3%) OR 17.0; 95% CI: 3.7-78.3; p < 0.001
Number of AEs excluding patients who
recently started treatment with FDCs
NE group: n = 132; E group: n = 63
1 (0.8%) 11 (17.5%) OR 27.1; 95% CI: 3.4-215.8; p < 0.001
Number of AEs excluding patients who
recently started treatment with efavirenz
NE group: n = 84; E group: n = 50
2 (2.4%) 12 (24.0%) OR 13.5; 95% CI: 2.9-63.5; p < 0.001
*AEs: adverse events; NE: non-exposed; E: exposed: FDCs: fixed-dose antiretroviral combinations; OR: odds ratio; 95%CI: confidence intervals at the 95% level.
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+1 in 47 (63%) patients. In 8 (12.6%) of these patients,
the FDCs were introduced after the appearance of AEs
that were likely related to ART. There were 6 (8%)Table 5 Description of adverse events that are likely related t
Adverse events Severity
(grade)
Non-exposed group (n = 150)
1. Dizziness after an error in taking AtriplaTM 1
2. Neuropsychiatric: insomnia, anxiety, and
abnormal dreams*
1
Exposed group (n = 75)
1. Neuropsychiatric: dizziness 2
2. Neuropsychiatric: insomnia, abnormal
dreams*
2
3. Neuropsychiatric: depression, insomnia* 1
4. Neuropsychiatric: insomnia 2
5. Diarrhoea 2
6. Vomiting 2
7. Hepatic toxicity 4
8. Neuropsychiatric: dizziness, insomnia, and
abnormal dreams*
2
9. Neuropsychiatric: insomnia, anxiety, loss of
concentration, abnormal dreams, and HIV
encephalopathy after stopping treatment*
4
10. Neuropsychiatric: dizziness 1
11. Psychiatric: depression, insomnia, anxiety,
abnormal dreams, and hallucinations*
3
12. Hepatic toxicity 3
13. Neuropsychiatric: dizziness, insomnia,
headache, and abnormal dreams*
2
14. Diarrhoea 2
*Patients with more than one type of neuropsychiatric adverse event. The grade ofpatients who received a new FDC in the exposed group,
and there were 4 (2.6%) patients who received a new
FDC in the non-exposed group. On visit +2, 21 exposed
patients continued with individual antiretroviral agents,o antiretroviral therapy
Resources consumed for the management









Specialist and nursing consults, hospital admissions,
chest x-rays, abdominal ultrasound, and hepatic biopsy
-
Infectious disease consults, hospital admissions,
cranial CAT scan, cerebral MRI, and lumbar puncture
-
Emergency department admission, mental health consult
Infectious disease consult, nursing, biochemistry,
serology, and abdominal ultrasound
Infectious disease consult
-
the more severe AE is specified.
Figure 2 Flow of exposed and non-exposed patients during visits +1 and +2.
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mean time that patients in the exposed group were trea-
ted with individual components of FDCs was 120 days.
In the non-exposed group, the average cost per patient
was 3,017.50 € during the study period, while the aver-
age cost per patient was 3,103.84 € in the exposed group
(Table 6). The greater average antiretroviral treatment
cost in the exposed group was due to the higher fre-
quency of AEs in this group of patients. Of the 14 AEs
that were likely related to ART in the exposed group, 6
AEs were related to the consumption of healthcare
resources. The management of adverse events in the
exposed group represented an additional cost of 230.26
€ per patient compared with the non-exposed group. In







Cost of ART during the
study period*
3,017.50 2,873.58 143.92
Cost of AEs during the
study period
0.00 230.26 −230.26
Average total cost during
the study period
3,017.50 3,103.84 −86.34
Total cost per day 25.22 25.94 −0.72
Alternative scenario
Cost of ART during the
study period
3,017.50 2,873.58 143.92
Cost of AEs during the
study period
0.00 230.26 −230.26
Cost of extra follow-up
visit during the study
period
0.00 345.83 −345.83
Total cost during the
study period
3,017.50 3,449.67 −432.17
Total cost per day 25.22 28.83 −3.61
*Study period = 120 days; ART: antiretroviral therapy; AEs: adverse events.observed AEs involved no additional costs. Nevertheless,
in the non-exposed group, the pharmaceutical cost per
patient (3,017.50 €) was higher than that in the exposed
group (2,873.58 €). Thus, considering the costs of ART
and those associated with AEs management, administra-
tion of individual antiretroviral agents rather than FDCs
increases the cost of daily treatment by 0.72 € per
patient.
The pharmaceutical cost has the greatest effect on the
total cost of the treatment. The pharmacological cost
represents 95% and 100% of the total cost in the exposed
and non-exposed patient groups, respectively.
Alternative scenario
The additional follow-up visit for patients in the exposed
group incurred an added cost of 345.83 € per patient
during the study period. Thus, considering the cost of
an extra follow-up visit, the total daily cost of the treat-
ment increased by 3.61 € per patient when antiretroviral
agents were administered separately rather than using
FDCs. In Table 6, the results are detailed for the base
case and for the alternative scenario.
Discussion
The lower cost of the treatment with separated individ-
ual antiretroviral agents rather than FDCs is associated
with lower pharmaceutical costs but is related to higher
total healthcare costs.
In 2010, 25 years had passed since the initiation of re-
search on active compounds against HIV replication.
During this time period, considerable advances were
made. Possibly, there is no other therapeutic field that
has obtained comparable results in such a short period
of time. The advances include the development of FDCs
that have improved the quality of life of patients with
HIV by facilitating patient compliance and adherence to
complex and life-long treatments [7]. Contrary to other
chronic diseases, irregular compliance to treatments for
HIV-1 infection can result in a definitive loss of efficacy
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ment of resistance to the antiretroviral agents that are
used for the treatment of the disease [8].
Emtricitabine and lamivudine are nucleoside analogue
reverse transcriptase inhibitors, also known as “XTC”
drugs. These two antiretroviral agents are similar in
terms of structure, antiretroviral activity, and selection
for the M1841/V mutation, which alone can comprom-
ise the response to both drugs. As a result, there is a
perception that emtricitabine and lamivudine are equiva-
lent and interchangeable. However, the replacement of
emtricitabine, which is present in some FDCs, with gen-
eric lamivudine may be therapeutically non-equivalent.
In this sense, recent studies suggest that combinations
of antiretrovirals with lamivudine may be associated with
higher rates of the M1841/V mutation than combina-
tions with emtricitabine [9,10]. Maserati et al. suggested
that this different rate of resistance to mutations may be
the result of the different pharmacokinetic properties of
lamivudine and emtricitabine [11].
In some recent studies, better results have been
observed in the achievement of virologic response in
patients treated with FDCs at risk of poor compliance,
and other studies have reported a lower risk of hospital
admission and less consumption of healthcare resources
in patients treated with FDCs that consist of a single
tablet per day [12,13]. While these studies do not dem-
onstrate a cause-effect relationship, they do suggest that
FDCs could increase the efficacy of ART and generate
long-term savings in healthcare costs. In our study, we
found a significant increase in AEs after break-up of the
FDCs, which was associated with a short-term increase
in healthcare costs.
As our study was based on clinical practice, all of the
exposed patients were aware of the change and were
most likely not in agreement with it; thus, we cannot
discard the possibility that the AEs were caused by a pla-
cebo effect, especially in the milder cases. Nevertheless,
this does not detract from the repercussions on daily
clinical practice. Interestingly, the exposed patients who
presented AEs were those who were under stable treat-
ment with an emtricitabine containing FDCs prior to
the treatment change. None of the exposed patients with
a previous lamivudine containing FDCs presented any
AEs after the FDCs break-up. Thus, the higher rate of
AEs in the exposed group it could be attributed to the
change of emtricitabine for lamivudine. However, these
results should be interpreted with caution as the number
of exposed patients from lamivudine containing FDCs
was low (n = 15) and because in general, lamivudine is
associated with few AEs.
In our study, there were no statistically significant dif-
ferences between both groups of patients in variables
such as age, gender, weight, mechanism of transmission,concomitant pathologies and type of ART, what other-
wise could have explained the higher rate of AEs in the
exposed group. The only statistically significant differ-
ence between exposed and non-exposed patients was the
HIV-1 viral load at visit −1 (prior to baseline visit), but
when a reanalysis was carried out excluding those
patients, the differences found in AEs appearance con-
tinued to be significant. At baseline visit, there were also
more patients with HIV-1 viral load > 50 copies/mL in
the exposed group compared with the non-exposed
group, without being this difference significant. When
those patients were excluded from the analysis, the dif-
ference in AEs between both groups remained statisti-
cally significant. Therefore, it seems unlikely that the
poorer control of the viral load in the exposed patients
could be the reason for the higher rate of AEs observed
in this group. Patients who recently started with ART
have also more probabilities of present AEs. Thereby, re-
analyses were carried out excluding patients with less
than 6 months under treatment with FDCs or efavirenz,
maintaining the differences in the AEs rate between both
groups of patients.
Among the AEs, neuropsychiatric events occurred
most frequently, which was similar to what was observed
at the initiation of efavirenz treatment, regardless of
whether the patients had been undergoing stable treat-
ment. Studies have demonstrated a relationship between
the presence of specific polymorphisms in cytochromes
CYP2B6, CYP2A6, and CYP3A4 and a higher risk of
neuropsychiatric toxicity that is associated with the dis-
continuation of efavirenz [14]; however, there is no evi-
dence of a different interaction of lamivudine and
emtricitabine with efavirenz. In contrast, in a study pub-
lished by Pollock et al., mild neuropsychiatric toxicity
was found in some patients who switched from lamivu-
dine to emtricitabine [15].
Although there are no data that demonstrate greater
toxicity of lamivudine compared to emtricitabine [16],
these AEs were clearly associated with FDCs disruption.
The severe AEs, which had significant cost repercus-
sions, were neuropsychiatric in three cases and hepato-
toxic in two cases.
No significant differences were found in the rate of
virologic failure between patients exposed and patients
not exposed to FDCs disruption. However, the number
of patients included in this study was small, the time of
exposure to the change was short (an average of
120 days), and the majority of patients returned to using
FDCs when their reintroduction was allowed.
Finally, it should be noted that the regional approval
to separately administer FDCs components implies the
access to different levels of healthcare quality according
to the geographic area of residence, despite the availabil-
ity of a common National Healthcare System in Spain.
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http://www.healtheconomicsreview.com/content/2/1/16One methodological limitation of this cost analysis is
that it was based on a single study centre and was not
randomised. Nevertheless, the data recorded during this
study reflect usual clinical practices. Efficacy parameters
for different strategies have not been considered, as the
objective of this study was not to perform a cost-
effectiveness analysis; rather, the objective of the study
was to analyse the possible savings that are associated
with FDCs discontinuation in Son Llàtzer Hospital.Conclusions
The results of this study suggest that breaking up FDCs
to separately administer the individual antiretroviral
agents leads to an increase in costs for the Son Llàtzer
Hospital. These additional costs were related to the
management of AEs and the additional follow-up visits
that require a change in ART in our hospital.
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